Answers are grounded in this paper and cite their sources.
T follicular helper (T FH ) cells are critical for humoral immunity against infections and correlate with immunotherapy efficacy, whereas immune checkpoint inhibitor therapy can drive their aberrant expansion, underscoring the need to understand the regulators controlling T FH cell fate. However, the epitranscriptomic regulation of their differentiation remains poorly understood. Here, we identify the 3-methylcytosine (m³C) methyltransferase METTL8 as a key regulator of T FH cell differentiation in both viral infection and cancer. METTL8 was preferentially expressed in CXCL13 hi T FH cells, and its deficiency impaired T FH differentiation and germinal center responses in the lymphocytic choriomeningitis virus infection model and following anti–PD-1 immunotherapy in tumor models. Mechanistically, METTL8 exerted dual functions: it bound and stabilized Tcf7 mRNA through m³C modification, and it interacted with TCF1 protein to regulate chromatin accessibility and 3D genome organization at key T FH -associated loci, including Cxcr5 and Il6ra . Notably, ginkgolic acid treatment suppressed T FH responses without compromising the antitumor efficacy of anti–PD-1 therapy, an effect associated with METTL8. Collectively, our findings identify METTL8 as an epitranscriptomic regulator linked to RNA modification, TCF1-associated transcriptional control, and chromatin architecture during T FH differentiation and suggest that modulation of this pathway may provide a strategy to tune T FH -driven immune responses.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: